About InCarda

Committed to developing transformative therapies for cardiac conditions.

InCarda Therapeutics, Inc. is a privately-held, clinical-stage biopharmaceutical company pioneering a novel approach of treating cardiovascular conditions by the inhalation route. A potential advantage of inhalation therapy is that it delivers medicine in the “first pass” to cardiac tissue, directly addressing affected regions of the heart. Inhaled routes of administration offer rapid effect, fast clearance and reduced exposure at lower doses and the potential to effectively balance efficacy and safety.

Our lead product under development is an inhaled therapy to treat acute episodes of paroxysmal atrial fibrillation (PAF), a widespread atrial arrhythmia. InCarda employs a de-risked approach by using approved drugs and devices with a long history of efficacy and safety in a new dosing paradigm.

We have a highly experienced, passionate team with a strong track record of development. We are also supported by a world-class group of experts and advisors.

Our Mission & Vision

Our mission is to develop transformative therapies by pioneering a novel approach of treating cardiovascular conditions and diseases by the inhalation route. Our vision is to enable a new paradigm for acute cardiac care, empowering patients to take control, feel better sooner and improve their health.

Our Core Values

Our Novel Approach

Our approach is designed to reduce the risks and timelines normally associated with drug development.
Our model is based on the following three tenets:


Known Heart Conditions with High Unmet Need

InCarda’s products target well-known heart diseases & conditions.

Known Drugs


Using approved drugs via novel inhalation is a unique paradigm for treating heart conditions which potentially reduces development risk.

New Delivery


The goal of our inhaled products is to more specifically and directly target the heart, potentially increasing therapy success while optimizing safety.

For more information about InCarda: